- Transforming Protocol to Execution: How AIKA uses advanced AI to streamline protocol generation, enhance feasibility analysis, and reduce study start-up timelines.
- Data-Driven Decision Support: Leveraging real-time operational insights and predictive analytics to improve trial performance and risk mitigation.
- Scaling Clinical Operations: Practical examples of AIKA in action, from automated task orchestration to cross-functional collaboration that drives efficiency and quality.
Archives: Agenda
Beyond expansion: Why Canada belongs in your primary trial strategy
With a disproportionately large number of patients willing to participate in global studies, Canada’s world-class researchers and diverse patient population, trial cost efficiency, robust health authority with reliable process times, consistent data quality, and national therapeutic expertise in oncology make it an attractive country for enrollment to your global clinical trial program. This presentation explores how to succeed with your oncology trial in Canada with insights on:
- The Perception Gap
- How Sponsors Receive: Predictability – Speed – Quality – Partner Accountability
- Competitive Structural Advantages
- Real-World Global Trial Examples
- What to Expect in a Partner for the Region
PRACTICAL KEYNOTE: From concept to clinic: Operationalizing the Pharmacy Card Model to decentralize supply and accelerate patient access
- Understanding the Pharmacy Card Model
- The program lifecycle: From design to delivery
- A day in life: Sponsors and sites
- Proof of performance: Feedback and case studies
KEYNOTE: Engaging CRO partners earlier: A collaborative outsourced operating model for faster early-phase oncology trials
- Building an operating model that aligns sponsors, CROs, and clinical sites around shared timelines and delivery expectations
- Operational strategies for condensing early-phase development timelines while maintaining trial quality and oversight
- Cellectar Biosciences case study: Lessons from a COO on partnering with CROs and clinical sites to rapidly execute studies and meet key clinical milestones
- Managing operational complexity when multiple partners support a single oncology program
Panel introduction by Shaily Arora
Driving Acceleration in Oncology Trials Through Contemporary Regulatory Strategies
- Modern FDA Acceleration Pathways: Breakthrough, Fast Track, Accelerated Approval, Priority Review, RTOR, Orbis, CNPV
- Trial Design Innovations That Regulators Support: adaptive designs, master protocols, biomarker‑driven enrichment
- Optimizing Early Regulatory Engagement to Enable Acceleration: strategic FDA/EMA interactions, alignment on endpoints and biomarkers
Chair’s opening remarks
Registration and refreshments
End of Conference
ROUNDTABLE SESSIONS
During the roundtable discussion session, the conference hall will be divided into zones. Delegates can choose which zone they would like to join. Each zone will be led by a table moderator and will focus on a different challenge within the industry. After 30 minutes, delegates will have the opportunity to swap and choose a different table, and each roundtable will run twice.
Navigating communication styles by tailoring approaches for different patient personalities
Roel van der Heijde, Facilitator & Trainer, Patient Experience Association The Netherlands
Managing Clinical Trial Budgets in An Unstable Financial World
Working Better with Investigative Sites
Working With CROs More Effectively